Pharma politcal donations "blocked new laws"

9 April 2006

The Washington DC, USA-based pressure-group, Center for Public Integrity has issued a new report, claiming that US drugmakers have spent millions of dollars - with some notable successes - to block price-control measures under consideration by individual US states.

The authors quote legislative data compiled by the National Conference of State Legislatures, finding that 33 states have enacted at least 66 separate pieces of legislation related to cutting drug costs since 2003. In addition, almost every state has tried to implement one or more prescription drug cost-saving measures since 2000.

The most industry lobbying reported was in California, the state with the largest prescription drug budget in the USA. Medi-Cal, the agency that administers the republic's Medicaid program, spends about $4.0 billion a year for prescription drugs. Drug companies and associations reported spending $8.9 million lobbying in the state in 2003 and 2004, one-fifth of their nationwide total.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight